-
Something wrong with this record ?
MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction
M. Horváth, V. Horváthová, P. Hájek, C. Štěchovský, J. Honěk, L. Šenolt, J. Veselka,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
Springer Nature - nature.com Journals - Fully Open Access
from 2011-12-01
- MeSH
- Acute Coronary Syndrome genetics MeSH
- Genetic Markers genetics MeSH
- ST Elevation Myocardial Infarction genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs genetics MeSH
- Coronary Artery Disease genetics MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We sought to analyse plasma levels of peripheral blood microRNAs (miRs) as biomarkers of ST-segment-elevation myocardial infarction (STEMI) due to type-1 myocardial infarction as a model situation of vulnerable plaque (VP) rupture. Samples of 20 patients with STEMI were compared both with a group of patients without angina pectoris in whom coronary angiogram did not reveal coronary atherosclerotic disease (no coronary atherosclerosis-NCA) and a group of patients with stable angina pectoris and at least one significant coronary artery stenosis (stable coronary artery disease-SCAD). This study design allowed us to identify miRs deregulated in the setting of acute coronary artery occlusion due to VP rupture. Based on an initial large scale miR assay screening, we selected a total of 12 miRs (three study miRs and nine controls) that were tested in the study. Two of the study miRs (miR-331 and miR-151-3p) significantly distinguished STEMI patients from the control groups, while ROC analysis confirmed their suitability as biomarkers. Importantly, this was observed in patients presenting early with STEMI, even before the markers of myocardial necrosis (cardiac troponin I, miR-208 and miR-499) were elevated, which suggests that the origin of miR-331 and miR-151-3p might be in the VP. In conclusion, the study provides two novel biomarkers observed in STEMI, which may be associated with plaque rupture.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028283
- 003
- CZ-PrNML
- 005
- 20210114153421.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-020-62835-w $2 doi
- 035 __
- $a (PubMed)32246100
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Horváth, Martin $u Department of Cardiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic. martin@horvath.cz.
- 245 10
- $a MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction / $c M. Horváth, V. Horváthová, P. Hájek, C. Štěchovský, J. Honěk, L. Šenolt, J. Veselka,
- 520 9_
- $a We sought to analyse plasma levels of peripheral blood microRNAs (miRs) as biomarkers of ST-segment-elevation myocardial infarction (STEMI) due to type-1 myocardial infarction as a model situation of vulnerable plaque (VP) rupture. Samples of 20 patients with STEMI were compared both with a group of patients without angina pectoris in whom coronary angiogram did not reveal coronary atherosclerotic disease (no coronary atherosclerosis-NCA) and a group of patients with stable angina pectoris and at least one significant coronary artery stenosis (stable coronary artery disease-SCAD). This study design allowed us to identify miRs deregulated in the setting of acute coronary artery occlusion due to VP rupture. Based on an initial large scale miR assay screening, we selected a total of 12 miRs (three study miRs and nine controls) that were tested in the study. Two of the study miRs (miR-331 and miR-151-3p) significantly distinguished STEMI patients from the control groups, while ROC analysis confirmed their suitability as biomarkers. Importantly, this was observed in patients presenting early with STEMI, even before the markers of myocardial necrosis (cardiac troponin I, miR-208 and miR-499) were elevated, which suggests that the origin of miR-331 and miR-151-3p might be in the VP. In conclusion, the study provides two novel biomarkers observed in STEMI, which may be associated with plaque rupture.
- 650 _2
- $a akutní koronární syndrom $x genetika $7 D054058
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a nemoci koronárních tepen $x genetika $7 D003324
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické markery $x genetika $7 D005819
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a infarkt myokardu s elevacemi ST úseků $x genetika $7 D000072657
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Horváthová, Veronika $u Faculty of Science, Charles University, Prague, Czech Republic. Department of Rheumatology, Charles University, 1st Faculty of Medicine and Rheumatology Institute, Prague, Czech Republic.
- 700 1_
- $a Hájek, Petr $u Department of Cardiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Štěchovský, Cyril $u Department of Cardiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Honěk, Jakub $u Department of Cardiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Šenolt, Ladislav $u Department of Rheumatology, Charles University, 1st Faculty of Medicine and Rheumatology Institute, Prague, Czech Republic.
- 700 1_
- $a Veselka, Josef $u Department of Cardiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 5845
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32246100 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153419 $b ABA008
- 999 __
- $a ok $b bmc $g 1608618 $s 1119463
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 1 $d 5845 $e 20200403 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20210105
